DEA Places Sedative Into Schedule IV
The Drug Enforcement Administration is placing the newly approved drug remimazolam in Schedule V of the Controlled Substances Act, it said in an interim final rule. Effective Oct. 6, remimazolam, which was granted approval by the Food and Drug Administration…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
in June, is subject to new registration, labeling, record-keeping, and import and export requirements. DEA is accepting comments on the rule until Nov. 5.